Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib in CBF-AML with KIT Mutations
NCT05821738Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avapritinib in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Composite Complete Remission at 36 months. Started Jun 2022; status: recruiting.
02
Drugs
avapritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05821738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821738.